Last reviewed · How we verify

NCT06874231: BRAINCONN

Brain Connectivity Marker for Alzheimer's Disease

Recruiting now Last updated 17 March 2025
What this trial tests

trial testing Neuroimaging in Alzheimer Disease in 120 participants. Currently enrolling.

Timeline
1 April 2023
Primary endpoint
31 July 2027
31 July 2027

Quick facts

Lead sponsorKarolinska Institutet
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment120
Start date1 April 2023
Primary completion31 July 2027
Estimated completion31 July 2027
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Karolinska Institutet

Who can join

Adults 40 to 85, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Neuroimaging

Trials testing the same drug.

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

Other Karolinska Institutet trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06874231.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing